An observational study in Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion, sponsored by Hoffmann-La Roche. Active, not recruiting at 299 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Hoffmann-La Roche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Retinal Vein Occlusion with a site in Japan — none open to participants now, 1 under way, none of them phase 3. Retinal Vein Occlusion · Japan.
Among the 19 studies in Retinal Vein Occlusion with a site in Japan, this one is the only one that started in 2022, is one of 4 observational ones, and was the 18th registered.
290 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 19 studies in Retinal Vein Occlusion with a site in Japan is open now. The open studies under Retinal Vein Occlusion, anywhere →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 9 · Phase 4 3
First in 1995; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 180 across 71 observational studies indexed under Retinal Vein Occlusion.
Median enrollment 177 across the 13 interventional studies, 3,193 across the 4 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 7 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
1 of the studies in Retinal Vein Occlusion with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476926Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Retinal Vein Occlusion with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
Patients being treated with specified Roche ophthalmology products approved in retinal indications in real-world, routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Have provided , as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.
Exclusion Criteria:
1. Concomitant participation of the patient in an ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faricimab
Drug: Faricimab
Combination Product: Port Delivery System with Ranibizumab
Drug: Faricimab
Drug: Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Also known as: VABYSMO™, RO6867461, RG7716
Drug page: Ranibizumab
The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
Also known as: SUSVIMO™, RG6321
Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline and 1 year
Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Retinal Indication and Product
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Number of Treatments Over Time, per Approved Retinal Indication and Product
Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)
Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product
Time frame: From Baseline until end of study (up to 5 years)
Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product
Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)
Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time, per Approved Retinal Indication and Product
Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)
Total Number of Visits per Year, per Approved Retinal Indication and Product
Time frame: Annually (up to 5 years)
Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product
Time frame: Annually (up to 5 years)
Time Interval Between Treatments per Year, per Approved Retinal Indication and Product
Time frame: Annually (up to 5 years)
Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per Approved Retinal Indication and Product
Time frame: From Baseline until end of study (up to 5 years)
Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and Product
Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product
Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)
Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product
Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.
Time frame: From Baseline until end of study (up to 5 years)
Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product
Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.
Time frame: From Baseline until end of study (up to 5 years)
Showing the first 100 of 299 sites across 29 countries. Choose a country and city above to see the rest.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.
Of 25 observational studies under Retinal Vein Occlusion, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 48 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.